Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 22, 2008 Jim Mueller	Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated.
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
The Motley Fool July 25, 2007 Brian Orelli	Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row.
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool October 24, 2007 Brian Orelli	Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool August 25, 2009 Brian Orelli	That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors.
Chemistry World January 8, 2013 Andrew Turley	Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
The Motley Fool April 27, 2007 Brian Orelli	Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note.
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
Chemistry World November 21, 2013 Phillip Broadwith	Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests.
The Motley Fool September 5, 2006 Dan Caplinger	How to Pick a Financial Advisor If you don't have the time or inclination to manage your finances on your own, it can be extremely beneficial to get help from an outside advisor. By following these basic suggestions, you can find a suitable advisor to keep you on the road to financial stability and independence.
The Motley Fool January 11, 2008 Brian Orelli	Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
Chemistry World April 19, 2013 Sarah Houlton	Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool January 3, 2012 Alex Planes	Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
The Motley Fool November 7, 2006 Dan Caplinger	When Your Advisor Quits Facing the retirement of a trusted financial advisor can be traumatic. By remaining objective and cautious during your transition to a new advisor, you can take steps to ensure that you will continue to receive the good advice you've come to expect.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
The Motley Fool July 13, 2006 Rick Aristotle Munarriz	Dueling Fools: Stock Options Bear Companies will have to scale back on exercising new grants or knock down their paychecks. Stock options, that wonderful concept on paper, has been abused badly by compensation committees. Investors, take note.
The Motley Fool October 25, 2007 Brian Orelli	Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter.
The Motley Fool October 30, 2006 Dan Caplinger	Avoid the Boiler Room Some financial advisors know more about sales than they do about investing. Finding good financial advice is tough. Investors with little or no knowledge about their finances are extremely vulnerable to disreputable professionals.
The Motley Fool May 31, 2006 Jim Mueller	Too Many Options on the Menu Stock-based compensation weighs down the earnings of restaurants, of all things. Is it really necessary, though, if you are an established, profitable restaurant chain?
The Motley Fool September 12, 2008 Brian Orelli	Monsanto Makes Half a Discovery Monsanto announces that it has sequenced the DNA of one of its "top-performing elite" lines of corn.
AskMen.com December 9, 2001 Rashmikant Patel	Trusting Your Advisor Many of us are looking back at our investments over the last couple of years, and blaming our advisors for the less than stellar performance. It all comes down to one issue: do you trust your financial advisor?
The Motley Fool July 25, 2008 Brian Orelli	Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.
Chemistry World October 13, 2015 Simon Hadlington	DNA movement through motor proteins measured Researchers have adapted a method for DNA sequencing to measure directly and with exquisite sensitivity the movement of a single molecule of DNA as it is drawn through specialized motor proteins.